Status:

UNKNOWN

Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea

Lead Sponsor:

keepMED Ltd.

Collaborating Sponsors:

CRI-The Clinical Research Institute GmbH

Conditions:

Obstructive Sleep Apnea

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A prospective, multi-centre, single-arm, open-label, interventional study with a non-marketed medical device. The primary study objective is to assess the efficacy of the keepMED PAP device on modifi...

Detailed Description

The study includes a baseline visit, a habituation night, and a therapy night. Both nights will be undertaken in the sleep lab under identical conditions and will include the keepMED PAP therapy activ...

Eligibility Criteria

Inclusion

  • Age ≥18 years.
  • Newly diagnosed OSA with AHI ≥ 15 events/hours.
  • Indication for OSA PAP therapy in routine clinical care according to applicable medical guidelines within one month prior to study enrolment.
  • Naïve to PAP therapy, i.e. even no PAP therapy during a PSG night.
  • Weight \> 30kg.
  • Signed informed consent.

Exclusion

  • Body Mass Index (BMI) of ≤20 kg/m² or ≥ 35 kg/m².
  • Pathologically low blood pressure (systolic ≤90mm Hg; diastolic ≤60 mm Hg).
  • Current unstable or serious medical conditions (such as angina pectoris, myocardial infarction, cancer, stroke, dementia, congestive heart failure) which based on the physician's judgment might put the patient at high risk.
  • Mixed and central apnea index ≥ 5 events/hour in PSG without PAP therapy.
  • Bullous lung disease.
  • Tracheostomy.
  • Pneumothorax.
  • Pneumocephalus.
  • Cerebrospinal fluid leak.
  • Current sinus or middle ear infection.
  • Persistent blockage of one or both nostrils (including nasal septum deviation and nasal polyps) or any other reason that leads to difficulty of breathing through the nose while awake.
  • Any nasal, facial or head abnormalities that would not allow adequate placement of the device.
  • Previous diagnosis of insomnia, narcolepsy or periodic limb movement disorder that in the judgment of the clinician could affect sleep quality assessment.
  • Chronic respiratory disease (COPD, pulmonary fibrosis or asthma) or FEV/FVC ≤ 60% in history.
  • History of respiratory failure.
  • Supplemental oxygen is required.
  • Uvulopalatopharyngoplasty or other surgical procedure to correct apnea.
  • Acute respiratory infection.
  • Subject recovered from Covid-19 but suffers from on-going symptoms or when subject's Covid-19 illness history can affect the study outcome based on the physician's judgment.
  • Pregnancy.
  • Medication that may alter sleep architecture.

Key Trial Info

Start Date :

September 14 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 28 2022

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT04875897

Start Date

September 14 2021

End Date

February 28 2022

Last Update

September 2 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.